NPM1 and acute myeloid leukemia: So far, the best pre-treatment predictors of outcomeregarding CR rate, disease-free survival (DFS),and OS in adult AML patients are karyotypic andmolecular abnormalities (e.g., fms-related receptortyrosine kinase 3 inter tandem duplication (FLT3-ITD)and nucleophosmin 1 (NPM1)) [3] incorporated in2022 European LeukemiaNet (ELN 2022) risk stratificationssystem for AML [1].